Independent Director Kenneth Kelley Just Bought Shares In Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Those following along with Halozyme Therapeutics, Inc. (NASDAQ:HALO) will no doubt be intrigued by the recent purchase of shares by Kenneth Kelley, Independent Director of the company, who spent a stonking US$749k on stock at an average price of US$14.23. Not only is that a big swing, but it increased their holding size by 23%, which is definitely great to see.

View our latest analysis for Halozyme Therapeutics

Halozyme Therapeutics Insider Transactions Over The Last Year

In the last twelve months, the biggest single sale by an insider was when the insider, Randal Kirk, sold US$31m worth of shares at a price of US$15.48 per share. So what is clear is that an insider saw fit to sell at around the current price of US$14.90. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.

In total, Halozyme Therapeutics insiders sold more than they bought over the last year. The chart below shows insider transactions (by individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Insider Ownership

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Halozyme Therapeutics insiders own about US$26m worth of shares. That equates to 1.2% of the company. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Do The Halozyme Therapeutics Insider Transactions Indicate?

It's certainly positive to see the recent insider purchase. But we can't say the same for the transactions over the last 12 months. The more recent transactions are a positive, but Halozyme Therapeutics insiders haven't shown the sustained enthusiasm that we look for, although they do own a decent number of shares, overall. Overall they seem reasonably aligned. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Halozyme Therapeutics. Every company has risks, and we've spotted 1 warning sign for Halozyme Therapeutics you should know about.

But note: Halozyme Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.